A Clinical Trial Acceleration Method

Non-adherence in clinical trials is a big issue leading to lack of study power, increase in sample size and additional costs. It even might masquerade as drug resistance and diminish the apparent magnitude of the drug effect. This caveat can be overcome by optimized candidate screening and randomization procedures, as recommended by the FDA for the enrichment of clinical studies. (FDA 2012)

Selecting the right study participants for inclusion in a clinical trial should involve more than just meeting the clinical criteria. It should ideally identify each candidate’s likelihood of staying in the study and adhering to the protocols, as well as provide insight into what each participant uniquely needs to stay engaged.

Now is the time to enrich your clinical trials and change the way you select your study participants.

STRATUM™. It’s Time for a Revelation.

“…Drug developers can use such strategies, known as clinical trial enrichment, to greatly increase the likelihood that data collected during a clinical trial will demonstrate that an effective drug is effective.

These are potentially powerful strategies for the pharmaceutical industry because appropriate use of enrichment could result in smaller studies, shortened drug development times, and lower development costs.”

Bob Temple, M.D., Deputy Director for Clinical
Science at the Food and Drug Administration (Temple 2012)


We welcome your questions and communication relating to our approach of Population Health Management. Please contact us directly for more information, or to set up a consultation.

Phone: +1 (844) 737 7664 (USA) or +49 (0)30 290 292 500 (Germany), Email:  (info@massineboecker.com), Contact Page.

FDA Guidance for Industry 2012
Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products

Temple B
Strategies for More Successful Drug Trials
FDA Voice 2012: http://blogs.fda.gov/fdavoice/index.php/2012/12/strategies-for-more- successful-drug-trials/